Efficacy and Safety of Intranasal MSP-2017 (Etripamil) for the Conversion of PSVT to Sinus Rhythm

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2015
The primary objective of this study is to demonstrate the superiority of at least 1 dose of intranasal (IN) MSP-2017 (Etripamil) over placebo in terminating PSVT induced in an electrophysiology (EP) laboratory.
Epistemonikos ID: 572c26226a809758274934c80033945698073ebb
First added on: May 12, 2024